Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | XPO1 | O14980 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666917 | 0.79 | TSHR (0.40) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL640114 | 0.79 | TSHR (0.40) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL9745938 | 0.78 | TSHR (0.36) | TSHRADRA1APDE4DXPO1LMNA | |
| SCHEMBL9746345 | 0.77 | TSHR (0.39) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL9244632 | 0.77 | TSHR (0.39) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL9745747 | 0.77 | TSHR (0.39) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL1520934 | 0.77 | TSHR (0.39) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL2065900 | 0.77 | TSHR (0.39) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL1242991 | 0.76 | TSHR (0.42) | TSHRADRA1APDE4DGAASMN1; SMN2 | |
| SCHEMBL3476792 | 0.76 | LMNA (0.44) | TSHRADRA1APDE4DGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016916-A1 | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016916-A1 | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014152263-A1 | EXO OLEFIN-CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-5100762-A | Radiation-sensitive polymer and radiation-sensitive composition containing the same | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016916-A1 | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof | XPO1, XPOT, XPO5 | TSHR 3727/4885ADRA1A 1055/4885PDE4D 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.